Macular Degeneration Website Links For
Macular Degeneration
 

Information About

Macular Degeneration




  ICD10 H353
  ICD9


cross-sectional view. Courtesy NIH National Eye Institute ]]

National Eye Institute ]]

Macular degeneration is a medical condition where the light sensing cells in the condition. These forms are sometimes called Juvenile macular degeneration (JMD). In macular degeneration the final form results in missing or blurred vision in the central, reading part of vision. The outer, peripheral part of the vision remains intact.


AGE RELATED MACULAR DEGENERATION

ARMD is further divided into a "dry," or nonexudative, form and a "wet," or exudative, form. Eighty five to ninety percent of cases are categorized as "dry" macular degeneration where fatty tissue, known as drusen, will slowly build up behind the Retina . Ten to fifteen percent of cases involve the growth of abnormal blood vessels under the retina. These cases are called "wet" macular degeneration due to the leakage of blood and other fluid from behind the retina into the eye. Wet macular degeneration usually begins as the dry form. If allowed to continue without treatment it will completely destroy the macula. Medical, Photodynamic , laser photocoagulation and laser treatment of wet macular degeneration are available.


Risk factors



Signs



Symptoms



The Amsler Grid Test is one of the simplest and most effective methods for patients to monitor the health of the macula. The Amsler Grid is essentially a pattern of intersecting lines (identical to graph paper) with a black dot in the middle. The central black dot is used for fixation (a place for the eye to stare at). With normal vision, all lines surrounding the black dot will look straight and evenly spaced with no missing or odd looking areas when fixating on the grid's central black dot. When there is disease affecting the macula, as in macular degeneration, the lines can look bent, distorted and/or missing.

The traditional Amsler grid test is a black and white pattern that may miss early defects (references at www.ixm.us ). Since treatment and vision preservation in macular degeneration is facilitated by early detection of the disease, a more sensitive blue-on-yellow Amsler grid test pattern has recently been introduced ( IXMUS Home Test ).

'Vision loss' or 'blindness' in macular degeneration refers to the loss of 'central vision' only. The peripheral vision is preserved. Blindness in macular degeneration does not mean 'inability to see light' and even with far advanced macular degeneration, the peripheral retina allows for useful vision.

The loss of central vision profoundly effects visual functioning. It is not possible, for example, to read without central vision. Pictures which attempt to depict the central visual loss of macular degeneration with a black spot do not really do justice to the devasting nature of the visual loss. This can be demonstrated by printing letters 6 inches high on a piece of paper and attempting to identify them while looking straight ahead and holding the paper slightly to the side. Most people find this surprisingly difficult to do.


Diagnosis

Fluorescein Angiography allows for the identification and localization of abnormal vascular processes.


Treatment

During the early stages of the disease, the neural layers of the retina remain relatively unaffected. This fact makes it a possible target for treatment with a retinal prosthesis, which are currently under development.


Prevention


Research on prevention of AMD

Several macular degeneration clinical trials are currently underway. The most promising approach is the anti- (Lucentis), Anecortave (Retaane), Bevacizumab (Avastin), Squalamine (Evizon) and SiRNA . Second generation antisense oligonucleotides ICo-007 targeting the Raf-1 kinase are also under investigation as a target for broad inhibition of multiple pro-angiogenic signals. The most promising of these treatments, Ranibizumab (Lucentis), is the 1st drug tested that has shown significant improvement in visual acuity in multiple phase III trials. Radiation therapy ( Brachytherapy ) and Rheopheresis are also being evaluated for wet macular degeneration {Link without Title} .

Recent studies suggest that Statin s, a family of drugs used for reducing Cholesterol levels, may be effective in prevention of AMD, and in slowing its progression {Link without Title} .

The Age-Related Eye Disease Study concluded that high levels of Antioxidant s and Zinc can reduce some people's risk of developing advanced AMD by about 25 percent.


JUVENILE MACULAR DEGENERATION

"Macular degeneration" is a descriptive term for any condition which leads to loss of function of the light sensitive cells at the center of the retina. Several rare hereditary conditions can lead to macular degeneration in children and adolescents. These include:


NOTES






SEE ALSO



EXTERNAL LINKS